Search

Search Constraints

You searched for: Author/Creator Carucci, P.

Search Results

3. OC.05.4 Y90-RADIOEMBOLIZATION VERSUS SORAFENIB IN LOCALLY ADVANCED HCC WITH INTRAHEPATIC NEOPLASTIC PORTAL VEIN THROMBOSIS: THE PIEDMONT-AOSTA VALLEY ONCOLOGY NETWORK EXPERIENCE. (1st October 2020)

4. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes a pro-tumorigenic inflammatory response. (March 2023)

6. PH-0499 SABR as a treatment option for HCC patients: efficacy and toxicity profile. (August 2021)

7. Risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis of viral etiology evaluated by the association of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II) and glypican-3 (GPC-3). (February 2020)

8. Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC). (10th February 2016)

9. The Piedmont-Aosta Valley Oncology Network experience in locally advanced HCC with intrahepatic neoplastic portal vein thrombosis: Y90-radioembolization versus Sorafenib. (February 2020)